Century TherapeuticsIPSC
Market Cap: $124M
About: Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.
Employees: 165
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
1,700% more call options, than puts
Call options by funds: $18K | Put options by funds: $1K
121% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 14
9.15% more ownership
Funds ownership: 35.98% [Q1] → 45.13% (+9.15%) [Q2]
0% less capital invested
Capital invested by funds: $97.5M [Q1] → $97.2M (-$230K) [Q2]
8% less funds holding
Funds holding: 66 [Q1] → 61 (-5) [Q2]
42% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 12
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Mitchell Kapoor 49% 1-year accuracy 58 / 119 met price target | 516%upside $9 | Buy Maintained | 15 Aug 2024 |
Piper Sandler Edward Tenthoff 31% 1-year accuracy 11 / 36 met price target | 722%upside $12 | Overweight Maintained | 17 Jun 2024 |